Optimizing immunosuppression with sirolimus in the first year posttransplantation: experience in the United States.

Weir, M R; Wali, R K

Weir, M R; Wali, R K.

Affiliation

Weir MR; Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21202, USA. mweir@medicine.umaryland.edu

Transplant Proc ; 41(6 Suppl): S13-7, 2009.

Article in En | MEDLINE | ID: mdl-19651289

Subject(s)

Immunosuppression Therapy/methods; Immunosuppressive Agents/therapeutic use; Kidney Transplantation/immunology; Sirolimus/therapeutic use; Diabetes Mellitus/epidemiology; Diabetes Mellitus/prevention & control; Follow-Up Studies; Graft Rejection/prevention & control; Humans; Kidney Transplantation/physiology; Postoperative Complications/epidemiology; Postoperative Complications/prevention & control; Randomized Controlled Trials as Topic; Time Factors; Treatment Failure; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Immunosuppression Therapy / Kidney Transplantation / Sirolimus / Immunosuppressive Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Transplant Proc Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google